Core Viewpoint - Hims & Hers Health, Inc. is under investigation for potential violations of federal securities laws following the termination of its partnership with Novo Nordisk due to allegations of deceptive marketing and safety risks associated with its products [1][3]. Group 1: Company Overview - Hims & Hers is a telehealth company that offers online consultations with licensed healthcare professionals, prescription medications, and wellness products [2]. - The company entered a "long-term collaboration" with Novo Nordisk to sell the weight loss drug Wegovy [2]. Group 2: Recent Developments - Novo Nordisk announced the termination of its partnership with Hims & Hers on June 23, 2025, citing accusations of "deceptive marketing" and the sale of illegitimate versions of Wegovy [3]. - Following the announcement, Hims & Hers' stock price dropped by $22.25 per share, a decline of over 34%, from $64.22 on June 20, 2025, to $41.97 on June 23, 2025 [3]. Group 3: Legal Implications - Bleichmar Fonti & Auld LLP is investigating Hims & Hers for potential legal actions related to the stock decline and allegations of misconduct [1][4]. - Investors in Hims & Hers are encouraged to seek legal options and submit their information to the law firm for potential representation [4]. Group 4: Law Firm Background - Bleichmar Fonti & Auld LLP is recognized as a leading international law firm specializing in securities class actions and shareholder litigation, with notable recoveries in past cases [5].

Core Viewpoint - Kaskela Law LLC is investigating Trevi Therapeutics, Inc. on behalf of the company's long-term investors to determine potential violations of securities laws or breaches of fiduciary duties by the company and its officers and directors [1][2]. Group 1 - The investigation is focused on recent corporate actions taken by Trevi Therapeutics [2]. - Shareholders of Trevi are encouraged to reach out to Kaskela Law LLC for more information regarding their legal rights and options [3]. - Kaskela Law LLC specializes in representing investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis [3].

Core Viewpoint - UroGen Pharma Ltd. is under investigation for potential securities fraud and unlawful business practices following negative FDA feedback on its bladder cancer drug UGN-102 [1][3]. Group 1: FDA Review and Trial Concerns - The FDA's briefing document highlighted that UroGen's Envision trial lacked a concurrent control arm, making the primary endpoints difficult to interpret [3]. - The FDA recommended a randomized trial design multiple times to address concerns regarding the trial's validity [3]. Group 2: Stock Price Impact - Following the FDA's briefing document release on May 16, 2025, UroGen's stock price dropped by $2.54, or 25.79%, closing at $7.31 per share [4]. - After the Oncologic Drugs Advisory Committee voted against the NDA for UGN-102 on May 21, 2025, the stock price fell further by $3.37, or 44.7%, closing at $4.17 per share [4].

Core Viewpoint - The investigation by Pomerantz LLP focuses on potential securities fraud or unlawful business practices by Boeing and its executives following a recent aircraft crash that negatively impacted the company's stock price [1][2]. Group 1: Incident Overview - On June 12, 2025, a Boeing 787 Dreamliner operated by Air India crashed shortly after takeoff in Ahmedabad, India [2]. - Following the crash, Boeing's stock price decreased by $13.68 per share, representing a 6.39% decline, closing at $200.32 per share on June 13, 2025 [2]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of investors of The Boeing Company regarding possible securities fraud or other unlawful business practices [1]. - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud and corporate misconduct [3].

Core Viewpoint - Dyne Therapeutics is facing an investigation regarding potential securities fraud or unlawful business practices following a delay in FDA approval for its experimental therapy DYNE-101 for myotonic dystrophy type 1 [1][2]. Group 1: Company Developments - On June 17, 2025, Dyne Therapeutics announced a delay in filing for FDA approval of DYNE-101, which is an experimental therapy for myotonic dystrophy type 1 [2]. - The company revised its protocol for the Phase 1/2 global ACHIEVE trial for DYNE-101 after a Type C meeting with the FDA, with the revised protocol submitted in June [2]. - Dyne now plans to complete enrollment in the Registrational Expansion Cohort by the fourth quarter of 2025, aiming for a data readout in mid-2026 and a potential Accelerated Approval submission in late 2026 [2]. Group 2: Market Reaction - Following the announcement of the delay, Dyne's stock price fell by $2.96 per share, representing a decline of 21.42%, closing at $10.86 per share on June 17, 2025 [3].

LOS ANGELES, June 18, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP, a leading national shareholder rights law firm, continues its investigation on behalf of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG) investors concerning the Company’s possible violations of the federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON NEOGEN CORPORATION (NEOG), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. What Happened? On June 4, 2025, Neogen disclosed tha ...

NEW YORK, June 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Petco Health and Wellness Company, Inc. (“Petco” or the “Company”) (NASDAQ: WOOF).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Petco and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class act ...

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Rocket Pharmaceuticals and its officers or directors [1] Group 1: Company Developments - On May 27, 2025, Rocket Pharmaceuticals announced an update regarding its investigational gene therapy RP-A501 for Danon disease, revealing that a patient in the Phase 2 trial experienced a Serious Adverse Event (SAE) related to capillary leak syndrome [3] - Following the SAE, Rocket paused further dosing in the study, and the FDA placed a clinical hold on the trial for further evaluation [3] - The patient involved in the SAE subsequently passed away due to an acute systemic infection [3] - As a result of this news, Rocket's stock price dropped by $3.94 per share, or 62.84%, closing at $2.33 per share on May 27, 2025 [3] Group 2: Legal and Investigative Actions - Pomerantz LLP is reaching out to investors of Rocket Pharmaceuticals to investigate claims of potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud and corporate misconduct [4]

BENSALEM, Pa., June 17, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith continues its investigation on behalf of Neogen Corporation (“Neogen” or the “Company”) (NASDAQ: NEOG) investors concerning the Company’s possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN NEOGEN CORPORATION (NEOG), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS. Contact the Law Offices of Howard G. Smith to discuss your legal rights by ...

Company Overview - EchoStar Corporation, along with its subsidiaries, provides networking technologies and services [3] Recent Developments - On May 12, 2025, The Wall Street Journal reported that the Federal Communications Commission (FCC) would investigate EchoStar's compliance with federal requirements for building a nationwide 5G network, leading to a stock price drop of over 16% [4] - On May 30, 2025, EchoStar announced it would not make a cash interest payment of approximately $326 million to allow time for the FCC to provide requested relief, resulting in an additional 12% decline in stock price [5] - On June 2, 2025, EchoStar disclosed it would similarly not make approximately $183 million in cash interest payments due to uncertainty from the FCC review, causing a further stock price drop of more than 11% [6] Legal Investigation - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving EchoStar, focusing on whether the company and its executives made false or misleading statements or failed to disclose material information to investors [1]